系统性红斑狼疮患者新冠病毒肺炎住院率：丹麦全国队列研究
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark.
作者信息
Cordtz René, Kristensen Salome, Dalgaard Louise Plank Holm, Westermann Rasmus, Duch Kirsten, Lindhardsen Jesper, Torp-Pedersen Christian, Dreyer Lene
机构信息
Department of Rheumatology, Aalborg University Hospital, 9000 Aalborg, Denmark.
Department of Rheumatology, Center for Rheumatology and Spine Diseases, Gentofte Hospital, 2900 Hellerup, Denmark.
出版信息
J Clin Med. 2021 Aug 27;10(17):3842. doi: 10.3390/jcm10173842.
BACKGROUND
Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection.
METHODS
This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with SLE compared with the general population in Cox-regression models. Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control study.
RESULTS
Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76-10.08) in SLE patients, and the corresponding hazard ratio was 2.54 (95% CI 1.55-4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment was associated with a HR for hospitalisation of 0.61 (95% CI 0.19-1.88), and 1.06 (95% CI 0.3-3.72) for glucocorticoid treatment.
CONCLUSION
Patients with SLE were at increased risk of hospitalisation with COVID-19.
背景
系统性红斑狼疮（SLE）患者由于免疫功能受损、疾病活动及治疗等因素，感染风险增加。本研究调查了SLE对COVID-19感染住院发生率的影响。
方法
这是一项丹麦全国性队列研究，时间跨度为2020年3月1日至2021年2月2日，基于多个全国性登记系统的关联数据。在Cox回归模型中，估计SLE患者与普通人群相比COVID-19住院的调整发病率。在SLE患者中，作为巢式病例对照研究分析住院的风险比（HR）。
结果
2533例SLE患者中有16例因COVID-19感染住院。SLE患者每1000人年的年龄性别调整率为6.16（95%CI 3.76 - 10.08），在调整合并症后，与匹配的普通人群组相比，相应的风险比为2.54（95%CI 1.55 - 4.16）。在SLE患者中，羟氯喹治疗与住院风险比为0.61（95%CI 0.19 - 1.88）相关，糖皮质激素治疗的风险比为1.06（95%CI 0.3 - 3.72）。
结论
SLE患者因COVID-19住院的风险增加。
Zotero 插件